secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2023-12-13T23:59:59+00:00
Accession:  0001628280-23-041394
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo/Pfizer Alta study: 4-year data shows mean ABR 1.4, sustained FVIII activity
--------------------------------------------------------------------------------

- Cohort 4 (3e13 vg/kg) mean ABR 1.4, median 0.0; 3 of 5 participants had zero bleeds post-infusion.
- FVIII activity maintained in mild-to-normal range in 4 of 5 participants over 4-year follow-up; 1 participant had FVIII BLOQ.
- No new safety signals; no thrombotic, neoplastic events, or FVIII inhibitors; LFT elevations resolved with steroids.
- Pfizer expects pivotal Phase 3 AFFINE readout mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828023041394/0001628280-23-041394-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828023041394/sgmo-20231211.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-041394

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer